Q: What is Alunbrig used for?

Alunbrig is used to treat anaplastic lymphoma kinase-positive non-small cell lung cancer .

Q: How does Alunbrig work?

Targeting ALK Proteins Alunbrig belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). It is specifically designed to treat non-small cell lung cancer that is caused by a defect in a gene called anaplastic lymphoma kinase (ALK). This genetic change causes the body to produce an abnormal ALK protein that sends constant signals telling cancer cells to grow and divide. How the Medication Works The medication works by identifying and attaching to these abnormal ALK proteins. Once attached, it blocks the signals that the proteins send to the cancer cells. By interfering with these pathways, Alunbrig can help: Slow down the growth of the tumor. Stop the cancer from spreading to other parts of the body. Shrink existing tumors. Overcoming Resistance In some cases, cancer cells can change or mutate to become resistant to other treatments. Alunbrig is designed to be effective against several different mutations of the ALK protein, including those that may have caused other similar medications to stop working. It also has the ability to inhibit other proteins, such as ROS1, which may play a role in cancer growth.

Q: What are the active ingredients in Alunbrig?

The active ingredient in Alunbrig is brigatinib .

Q: What are the side effects of Alunbrig?

Common side effects of Alunbrig may include: Nausea Diarrhea Fatigue and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Alunbrig?

Alunbrig belongs to the ALK inhibitor drug class.

Q: What is the dosage of Alunbrig and how do I take it?

How to Take Alunbrig Alunbrig is taken by mouth once every day. When taking this medication, follow these guidelines: Swallow the tablet whole. Do not crush, chew, or break the tablet. You may take the medication with or without food. Treatment typically begins with a lower dose for the first several days. If the medication is tolerated well, the dose is usually increased for the remainder of the treatment period as directed by a healthcare provider. Missed Doses If you miss a dose of Alunbrig, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at the same time to make up for a missed one. Vomiting After a Dose If you vomit after taking a dose of Alunbrig, do not take an extra dose. Wait until your next scheduled time to take the medication.

Q: Is Alunbrig safe during pregnancy and breastfeeding?

Pregnancy Considerations Alunbrig can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action and findings from animal studies, this medication may cause birth defects or the loss of a pregnancy. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant. Contraception Because of the risks to a developing fetus, specific contraceptive measures are recommended: Females: Individuals who can become pregnant should use effective non-hormonal contraception during treatment and for at least 4 months after the final dose. Alunbrig may interact with and decrease the effectiveness of hormonal contraceptives, such as birth control pills, patches, or implants. Males: Men with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. Breastfeeding It is not known if Alunbrig passes into human breast milk. Due to the potential for serious adverse reactions in a breastfed infant, it is advised that individuals do not breastfeed during treatment and for 1 week after the last dose. Fertility This medication may impair fertility in males. The long-term effects on fertility are not fully known, so individuals should discuss family planning concerns with their healthcare provider.

Q: What is the FDA approval status of Alunbrig?

FDA Approval History The U.S. Food and Drug Administration (FDA) first granted accelerated approval to Alunbrig in April 2017. This initial approval was for patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who had previously been treated with crizotinib but experienced disease progression or intolerance. In May 2020, the FDA expanded the approval to include the first-line treatment of adult patients with ALK-positive metastatic NSCLC. This allows the medication to be used as the initial therapy for patients whose cancer has spread. Regulatory Requirements Alunbrig is indicated only for patients whose tumors have been confirmed as ALK-positive using an FDA-approved diagnostic test. While the medication does not require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA-approved labeling includes specific warnings regarding potential serious adverse reactions. Interstitial Lung Disease (ILD)/Pneumonitis: Severe or life-threatening lung inflammation has been reported, particularly during the first week of treatment. Monitoring: The FDA requires monitoring for hypertension, bradycardia, visual changes, and elevations in muscle or pancreatic enzymes during therapy. Embryo-Fetal Toxicity: Based on its mechanism of action, the FDA warns that Alunbrig can cause fetal harm when administered to pregnant women.

Question 1

What is Alunbrig?

Accepted Answer

Alunbrig is a kinase inhibitor that works by blocking the action of abnormal proteins that signal cancer cells to multiply. By targeting these specific proteins, the medication helps to slow or stop the spread of the disease within the body.

This medication belongs to a group of drugs known as antineoplastics. It focuses on inhibiting signaling pathways that are essential for the survival and proliferation of certain malignant cells.

Question 2

What is Alunbrig used for?

Accepted Answer

Alunbrig is used to treat anaplastic lymphoma kinase-positive non-small cell lung cancer.

Question 3

How does Alunbrig work?

Accepted Answer

Targeting ALK Proteins

Alunbrig belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). It is specifically designed to treat non-small cell lung cancer that is caused by a defect in a gene called anaplastic lymphoma kinase (ALK). This genetic change causes the body to produce an abnormal ALK protein that sends constant signals telling cancer cells to grow and divide.

How the Medication Works

The medication works by identifying and attaching to these abnormal ALK proteins. Once attached, it blocks the signals that the proteins send to the cancer cells. By interfering with these pathways, Alunbrig can help:

Slow down the growth of the tumor.
Stop the cancer from spreading to other parts of the body.
Shrink existing tumors.

Overcoming Resistance

In some cases, cancer cells can change or mutate to become resistant to other treatments. Alunbrig is designed to be effective against several different mutations of the ALK protein, including those that may have caused other similar medications to stop working. It also has the ability to inhibit other proteins, such as ROS1, which may play a role in cancer growth.

Question 4

What are the active ingredients in Alunbrig?

Accepted Answer

The active ingredient in Alunbrig is brigatinib.

Question 5

What are the side effects of Alunbrig?

Accepted Answer

Common side effects of Alunbrig may include:

Nausea
Diarrhea
Fatigue
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Alunbrig?

Accepted Answer

Alunbrig belongs to the ALK inhibitor drug class.

Question 7

What is the dosage of Alunbrig and how do I take it?

Accepted Answer

How to Take Alunbrig

Alunbrig is taken by mouth once every day. When taking this medication, follow these guidelines:

Swallow the tablet whole. Do not crush, chew, or break the tablet.
You may take the medication with or without food.

Treatment typically begins with a lower dose for the first several days. If the medication is tolerated well, the dose is usually increased for the remainder of the treatment period as directed by a healthcare provider.

Missed Doses

If you miss a dose of Alunbrig, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at the same time to make up for a missed one.

Vomiting After a Dose

If you vomit after taking a dose of Alunbrig, do not take an extra dose. Wait until your next scheduled time to take the medication.

Question 8

Is Alunbrig safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy Considerations

Alunbrig can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action and findings from animal studies, this medication may cause birth defects or the loss of a pregnancy. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant.

Contraception

Because of the risks to a developing fetus, specific contraceptive measures are recommended:

Females: Individuals who can become pregnant should use effective non-hormonal contraception during treatment and for at least 4 months after the final dose. Alunbrig may interact with and decrease the effectiveness of hormonal contraceptives, such as birth control pills, patches, or implants.
Males: Men with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose.

Breastfeeding

It is not known if Alunbrig passes into human breast milk. Due to the potential for serious adverse reactions in a breastfed infant, it is advised that individuals do not breastfeed during treatment and for 1 week after the last dose.

Fertility

This medication may impair fertility in males. The long-term effects on fertility are not fully known, so individuals should discuss family planning concerns with their healthcare provider.

Question 9

What forms and strengths does Alunbrig come in?

Accepted Answer

Alunbrig is supplied as a film-coated tablet for oral administration. It is intended to be swallowed whole and is typically taken once per day.

Oral tablet

Question 10

What is the FDA approval status of Alunbrig?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first granted accelerated approval to Alunbrig in April 2017. This initial approval was for patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who had previously been treated with crizotinib but experienced disease progression or intolerance.

In May 2020, the FDA expanded the approval to include the first-line treatment of adult patients with ALK-positive metastatic NSCLC. This allows the medication to be used as the initial therapy for patients whose cancer has spread.

Regulatory Requirements

Alunbrig is indicated only for patients whose tumors have been confirmed as ALK-positive using an FDA-approved diagnostic test. While the medication does not require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA-approved labeling includes specific warnings regarding potential serious adverse reactions.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe or life-threatening lung inflammation has been reported, particularly during the first week of treatment.
Monitoring: The FDA requires monitoring for hypertension, bradycardia, visual changes, and elevations in muscle or pancreatic enzymes during therapy.
Embryo-Fetal Toxicity: Based on its mechanism of action, the FDA warns that Alunbrig can cause fetal harm when administered to pregnant women.

Question 11

What should I know about Alunbrig and cost?

Accepted Answer

The price of Alunbrig is influenced by several factors, as it is a specialized prescription medication used for specific types of lung cancer. These factors include:

Insurance Coverage: Most private insurance plans and Medicare provide coverage for Alunbrig, but out-of-pocket costs like copayments or coinsurance depend on the specific plan's formulary and tier structure.
Pharmacy Selection: Alunbrig is often classified as a specialty medication. It may only be available through specific specialty pharmacies, which can impact the final cost to the patient.
Financial Assistance: Patients may be eligible for support programs or copay assistance provided by the manufacturer to help manage the expenses associated with this treatment.

Because costs are subject to change and vary by individual circumstances, patients are encouraged to contact their insurance provider or pharmacist for the most current pricing information. Healthcare providers can also provide guidance on navigating financial assistance options.

Alunbrig

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Alunbrig

Hospitals.net Disclosure